Immunotherapy boosts standard treatment for cervical cancer?
NCT ID NCT03612791
First seen Apr 08, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tested whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with locally advanced cervical cancer. About 189 participants received either the combination or standard treatment alone. The goal was to see if the drug delays cancer progression, but ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.